More than 25 Years of Archived Biomedical and Pharmacological Records Acessible in Electronic Format

Thomson CorporationThomson Scientific, part of The Thomson Corporation (NYSE: TOC; TSX: TOC) and leading provider of information solutions to the worldwide research and business communities, today announced that it has added EMBASE® Classic to the Dialog® (File 772) and DataStar® (EM73, EMXX) platforms, providing access to more than 25 years of archived life sciences data available for the first time in electronic format.

EMBASE Classic, produced by Elsevier, includes the bibliographic records originally published in the 43 Excerpta Medica abstract print journals from 1947 through 1973. The fully digitized database is drawn from approximately 3,400 international journal titles, with a focus on European and North American published literature including non-English language articles. EMBASE Classic contains more than 1.8 million records from the biomedical and pharmacological literature. The historical data in EMBASE Classic, combined with up-to-date records in the EMBASE database (File 73/EMZZ), gives researchers approximately 60 years of information regarding medical and drug-related subjects.

"With EMBASE Classic, researchers can now review advancements made during an extremely fertile period for the sciences, particularly in the areas of molecular biology, marine sciences, vaccines and other drug therapies," said Geoffrey Dick, Director of Publisher Management, Thomson Scientific. "The archived literature should prove invaluable in reviews of toxicology, adverse events and prior art for patent prosecution."

EMBASE Classic enhances research in:

  • Drug development
  • Pipeline intelligence
  • Designing and mounting clinical investigations
  • New uses for old drugs
  • Approved uses for drugs
  • Adverse events and reactions monitoring on old drugs or endogenous compounds
  • Preparation of new drug applications
  • Product safety and compliance monitoring

EMBASE Classic significantly expands the collection of biomedical and pharmacological literature sought by research professionals. The new database complements current Dialog and DataStar life sciences offerings, including EMBASE® (1974+ in File 73/EMZZ), as well as the recently added BIOSIS Previews® (File 5/BIOL), Zoological Record Online® and MEDLINE (1951+ in File 155/MEZZ) archive data.

For more information about the EMBASE Classic database on Dialog and DataStar, visit www.dialog.com/embaseclassic.

About The Thomson Corporation
The Thomson Corporation is a global leader in providing essential electronic workflow solutions to business and professional customers. With operational headquarters in Stamford, Conn., Thomson provides value-added information, software tools and applications to professionals in the fields of law, tax, accounting, financial services, scientific research and healthcare. The Corporation's common shares are listed on the New York and Toronto stock exchanges (NYSE: TOC; TSX: TOC).

Thomson Scientific is a business of The Thomson Corporation. Its information solutions assist professionals at every stage of research and development-from discovery to analysis to product development and distribution. Thomson Scientific information solutions can be found at http://scientific.thomson.com.

Most Popular Now

Swissmedic begins rolling review of Moderna's mRNA…

Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for...

Moderna's COVID-19 vaccine candidate meets its pri…

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for...

Pfizer and BioNTech conclude Phase 3 study of COV…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that, after conducting the final efficacy analysis in their ongoing Phase 3 study, their mRNA-based...

Pfizer and BioNTech to submit Emergency Use Author…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced they will submit a request today to the U.S. Food and Drug Administration (FDA) for Emergency Use Authori...

Phase 2 trial of Oxford COVID-19 vaccine in health…

The UK's vaccine against SARS-CoV-2 shows similar safety and immunogenicity results in healthy older adults (aged 56 years and over) to those seen in adults aged 18-55 ye...

Lilly's neutralizing antibody bamlanivimab (LY-CoV…

The U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) for Eli Lilly and Company's (NYSE: LLY) investigational neutralizing antibody bamlan...

Chinese vaccine candidate based on inactivated SAR…

Results from an early-phase randomised clinical trial of a Chinese vaccine candidate based on the inactivated whole SARS-CoV-2 virus (CoronaVac) are published in The Lanc...

Medicago and GSK announce start of Phase 2/3 clini…

Medicago, a biopharmaceutical company headquartered in Quebec City, and GSK have announced the start of Phase 2/3 clinical trials of its plant-derived vaccine candidate f...

European Commission approves contract with BioNTec…

Today, the European Commission approved a fourth contract with pharmaceutical companies BioNTech and Pfizer, which provides for the initial purchase of 200 million doses ...

Pre-existing coronavirus antibodies could help pro…

Researchers at the Francis Crick Institute and University College London have found that some antibodies, created by the immune system during infection with common cold c...

Fluvoxamine may prevent serious illness in COVID-1…

In a preliminary study of COVID-19 patients with mild-to-moderate disease who were attempting to recover in their homes, researchers at Washington University School of Me...

The Sputnik V COVID-19 vaccine efficacy amounted t…

The National Research Center for Epidemiology and Microbiology named after N.F. Gamaleya of the Ministry of Health of the Russian Federation (Gamaleya Center) and the Rus...